Caliber Imaging & Diagnostics, Inc.
LCDX
Other OTC0.00
USD
- -
- -
Caliber Imaging & Diagnostics, Inc.
LCDX
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Caliber Imaging & Diagnostics, Inc. (LCDX) develops, manufactures and markets in vivo and ex vivo confocal microscopy imaging systems that enable cellular-level visualization of skin and other tissues for dermatology, pathology, research and surgical applications. The company offers VivaScope 1500, a reflectance confocal imaging system for capturing high-resolution images up to 8 x 8 mm of living tissue structures including the epidermis and superficial dermis; VivaScope 3000, a hand-held in vivo confocal microscope for flexible skin imaging and real-time optical biopsy; VivaScope 2500 with Digital H&E technology for rapid fluorescence and reflection imaging of stained fresh tissue samples; VivaScan software for patient scheduling, lesion imaging, review, reporting and storage; and VivaNet, a digital telepathology platform for remote image sharing and consultation. Products target clinicians, researchers and physicians focused on non-invasive skin cancer detection, lesion margin delineation, neuroscience specimen imaging and translational research, with operations centered in the United States and distribution through long-term European partnerships. Founded in 1991 as Lucid Technologies, Inc. and renamed Caliber Imaging & Diagnostics, Inc. in 2012, the company maintains headquarters at 100 Burtt Road, Suite 203, Andover, Massachusetts, with manufacturing facilities at 50 Methodist Hill Drive, Suite 1000, Rochester, New York. In August 2022, Caliber Imaging & Diagnostics signed a definitive merger agreement with VivaScope GmbH, a newly formed entity from MAVIG GmbH's VivaScope sales, marketing and support operations in Munich, Germany, under which Caliber stockholders receive VivaScope shares at a ratio of 0.0000091268 per Caliber share plus cash in lieu of fractions valued at $0.0088; the transaction, aimed at creating an integrated global confocal microscopy provider, remains subject to regulatory approvals with no subsequent public updates confirming closure as of late 2025. Earlier, the company entered a strategic advisory agreement with H.C. Wainwright & Co. to support expansion efforts. No further funding rounds, acquisitions, product launches or operational shifts appear in recent public disclosures.